The Collapse of 2022 Has Begun
Almost every asset you own could be in grave danger -- stocks, bonds, real estate and even banks.

Today, Dr. Martin Weiss reveals his survival plan for these unprecedented times.

Protect your wealth now.

Raquel Izumi Biography and Net Worth

Insider of Vincerx Pharma

Raquel Izumi, PhD is the Chief Operations Officer and President of Vincerx and a member of the Vincerx board of directors. Dr Izumi has served as Vincerx’s Chief Operations Officer and as a member Vincerx’s board of directors since March 2019. Before that, Dr Izumi co-founded Acerta Pharma and served as its executive vice president of clinical development from February 2013 to May 2020.  Dr Izumi also co-founded Aspire Therapeutics LLC and served as its chief scientific officer from June 2011 to February 2013. Before founding Aspire Therapeutics, Dr Izumi served as senior director of clinical development at Pharmacyclics LLC, a biopharmaceutical company, from February 2010 to May 2011, where she worked on designing and implementing seven clinical studies across various hematologic malignancies (including three studies that garnered breakthrough therapy designation) for the first BTK inhibitor (IMBRUVICA®) to enter clinical trials.  Dr Izumi began her research career at Amgen, where she held positions of increasing responsibility and participated in a successful BLA filing and approval for ARANESP®.  

Dr Izumi was a Howard Hughes Predoctoral Fellow at the University of California, Los Angeles where she obtained a PhD in microbiology and immunology. She received honors and distinction for her BA in biological sciences from the University of California, Santa Barbara.

What is Raquel E. Izumi's net worth?

The estimated net worth of Raquel E. Izumi is at least $55,200.00 as of June 27th, 2022. Dr. Izumi owns 40,000 shares of Vincerx Pharma stock worth more than $55,200 as of October 1st. This net worth estimate does not reflect any other investments that Dr. Izumi may own. Learn More about Raquel E. Izumi's net worth.

How old is Raquel E. Izumi?

Dr. Izumi is currently 52 years old. There are 3 older executives and no younger executives at Vincerx Pharma. The oldest executive at Vincerx Pharma is Mr. Tom C. Thomas J.D., Founder, Gen. Counsel & Chief Legal Officer, who is 63 years old. Learn More on Raquel E. Izumi's age.

What is Raquel E. Izumi's salary?

As the Insider of Vincerx Pharma, Inc., Dr. Izumi earned a total compensation package of $15,777.00 in 2020. Dr. Izumi earned a salary of $15,777.00, and no other miscellaneous compensation. Learn More on Raquel E. Izumi's salary.

How do I contact Raquel E. Izumi?

The corporate mailing address for Dr. Izumi and other Vincerx Pharma executives is 260 SHERIDAN AVENUE SUITE 400, PALO ALTO CA, 94306. Vincerx Pharma can also be reached via phone at 650-800-6676. Learn More on Raquel E. Izumi's contact information.

Has Raquel E. Izumi been buying or selling shares of Vincerx Pharma?

Raquel E. Izumi has not been actively trading shares of Vincerx Pharma in the last ninety days. Most recently, on Monday, June 27th, Raquel E. Izumi bought 40,000 shares of Vincerx Pharma stock. The stock was acquired at an average cost of $1.41 per share, with a total value of $56,400.00. Following the completion of the transaction, the insider now directly owns 40,000 shares of the company's stock, valued at $56,400. Learn More on Raquel E. Izumi's trading history.

Who are Vincerx Pharma's active insiders?

Vincerx Pharma's insider roster includes Laura Bushnell (Director), Ahmed Hamdy (CEO), Raquel Izumi (Insider), Andrew McDonald (Director), Alexander Seelenberger (CFO), and Tom Thomas (Insider). Learn More on Vincerx Pharma's active insiders.

Are insiders buying or selling shares of Vincerx Pharma?

During the last year, Vincerx Pharma insiders bought shares 8 times. They purchased a total of 109,869 shares worth more than $274,555.74. The most recent insider tranaction occured on August, 24th when Director Christopher P Lowe bought 18,400 shares worth more than $30,360.00. Insiders at Vincerx Pharma own 23.6 % of the company. Learn More about insider trades at Vincerx Pharma.

Information on this page was last updated on 8/24/2022.

Raquel E. Izumi Insider Trading History at Vincerx Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/27/2022Buy40,000$1.41$56,400.0040,000View SEC Filing Icon  
8/4/2021Buy1,000$11.96$11,960.00View SEC Filing Icon  
See Full Table

Raquel E. Izumi Buying and Selling Activity at Vincerx Pharma

This chart shows Raquel E Izumi's buying and selling at Vincerx Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vincerx Pharma Company Overview

Vincerx Pharma logo
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $1.38
Low: $1.08
High: $1.40

50 Day Range

MA: $1.43
Low: $1.03
High: $1.72

2 Week Range

Now: $1.38
Low: $1.00
High: $17.49


137,762 shs

Average Volume

130,895 shs

Market Capitalization

$29.24 million

P/E Ratio


Dividend Yield



The Collapse of 2022 Has Begun
Almost every asset you own could be in grave danger -- stocks, bonds, real estate and even banks.

Today, Dr. Martin Weiss reveals his survival plan for these unprecedented times.

Protect your wealth now.